Clinical Trial Update: Daratumumab With DCEP for Multiple Myeloma With Plasmacytoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating daratumumab in combination with DCEP for relapsed multiple myeloma with plasmacytoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma
• Plasmacytoma

Drugs mentioned

• Daratumumab (daratumumab)

Snippet

Sponsor: Seoul National University Hospital | Conditions: Multiple Myeloma in Relapse, Plasmacytoma | Phase 2 | Status: UNKNOWN